Impact of a VA-ECMO in Combination with an Extracorporeal Cytokine Hemadsorption System in Critically Ill Patients with Cardiogenic Shock-Design and Rationale of the ECMOsorb Trial.
CytoSorb®
ECMO
ICU
acute heart failure
cytokine removal
extracorporeal mechanical circulatory support
shock
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
25 Jul 2023
25 Jul 2023
Historique:
received:
26
05
2023
revised:
12
07
2023
accepted:
17
07
2023
medline:
12
8
2023
pubmed:
12
8
2023
entrez:
12
8
2023
Statut:
epublish
Résumé
Cardiogenic shock and arrest present as critical, life-threatening emergencies characterized by severely compromised tissue perfusion and inadequate oxygen supply. Veno-arterial extracorporeal membrane oxygenation (VA-ECMO) serves as a mechanical support system for patients suffering shock refractory to conventional resuscitation. Despite the utilization of VA-ECMO, clinical deterioration due to systemic inflammatory response syndrome (SIRS) resulting from the underlying shock and exposure of blood cells to the artificial surfaces of the ECMO circuit may occur. To address this issue, cytokine adsorbers offer a valuable solution by eliminating blood proteins, thereby controlling SIRS and potentially improving hemodynamics. Consequently, a prospective, randomized, blinded clinical trial will be carried out with ECMOsorb. ECMOsorb is a single-center, controlled, randomized, triple-blinded trial that will compare the hemodynamic effects of treatment with a VA-ECMO in combination with a cytokine adsorber (CytoSorb The ECMOsorb trial seeks to assess the efficacy of a cytokine adsorber (CytoSorb
Sections du résumé
BACKGROUND
BACKGROUND
Cardiogenic shock and arrest present as critical, life-threatening emergencies characterized by severely compromised tissue perfusion and inadequate oxygen supply. Veno-arterial extracorporeal membrane oxygenation (VA-ECMO) serves as a mechanical support system for patients suffering shock refractory to conventional resuscitation. Despite the utilization of VA-ECMO, clinical deterioration due to systemic inflammatory response syndrome (SIRS) resulting from the underlying shock and exposure of blood cells to the artificial surfaces of the ECMO circuit may occur. To address this issue, cytokine adsorbers offer a valuable solution by eliminating blood proteins, thereby controlling SIRS and potentially improving hemodynamics. Consequently, a prospective, randomized, blinded clinical trial will be carried out with ECMOsorb.
METHODS AND STUDY DESIGN
METHODS
ECMOsorb is a single-center, controlled, randomized, triple-blinded trial that will compare the hemodynamic effects of treatment with a VA-ECMO in combination with a cytokine adsorber (CytoSorb
CONCLUSIONS
CONCLUSIONS
The ECMOsorb trial seeks to assess the efficacy of a cytokine adsorber (CytoSorb
Identifiants
pubmed: 37568295
pii: jcm12154893
doi: 10.3390/jcm12154893
pmc: PMC10420280
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : CytoSorbents (Germany)
ID : Vertrag Nr. I 5630
Références
Resuscitation. 2016 Jun;103:106-116
pubmed: 26851058
Crit Care. 2016 Jul 04;20(1):208
pubmed: 27374027
Resuscitation. 2018 Sep;130:44-48
pubmed: 29738799
Lancet. 2008 Aug 16;372(9638):554-61
pubmed: 18603291
Crit Care Med. 2015 Jun;43(6):1223-32
pubmed: 25756419
Crit Care. 2021 Jan 28;25(1):41
pubmed: 33509234
Crit Care Med. 2015 Jan;43(1):57-64
pubmed: 25083980
Crit Care. 2023 May 31;27(1):215
pubmed: 37259160
N Engl J Med. 2010 Mar 4;362(9):779-89
pubmed: 20200382
J Card Surg. 1999 Jul-Aug;14(4):288-93
pubmed: 10874615
Crit Care Med. 2003 Jan;31(1):323-4
pubmed: 12545045
Blood Purif. 2019;48(3):203-214
pubmed: 31096211
N Engl J Med. 2018 Mar 01;378(9):797-808
pubmed: 29347874
JAMA. 2013 Mar 20;309(11):1154-62
pubmed: 23512062
Crit Care Med. 2011 Feb;39(2):259-65
pubmed: 20975548
Resuscitation. 2010 Oct;81(10):1219-76
pubmed: 20956052
JACC Cardiovasc Interv. 2017 Dec 26;10(24):e231-e233
pubmed: 29198456
Crit Care. 2009;13(6):R181
pubmed: 19917106
Crit Care Med. 2004 Jan;32(1):21-30
pubmed: 14707556
Resuscitation. 2021 Apr;161:61-79
pubmed: 33773833
Anaesthesist. 2018 Aug;67(8):607-616
pubmed: 30014276
N Engl J Med. 1991 Feb 14;324(7):429-36
pubmed: 1988827
Resuscitation. 2015 Oct;95:100-47
pubmed: 26477701
JACC Cardiovasc Interv. 2017 Dec 11;10(23):2469-2471
pubmed: 29217014
Crit Care Med. 2004 Mar;32(3):801-5
pubmed: 15090965
J Cardiothorac Surg. 2013 Aug 29;8:186
pubmed: 23985062
Minerva Anestesiol. 1999 Jun;65(6):410-8
pubmed: 10394812
Eur Heart J. 2021 Sep 21;42(36):3599-3726
pubmed: 34447992
Arch Intern Med. 2007 Aug 13-27;167(15):1655-63
pubmed: 17698689
Herz. 2017 Feb;42(1):27-44
pubmed: 28127638
Clin Res Cardiol. 2016 Apr;105(4):283-96
pubmed: 26608160
Crit Care. 2014 Dec 20;18(6):699
pubmed: 25527094
Crit Care. 2017 Jun 22;21(1):157
pubmed: 28637497